Zhang Hongzheng, Kim Sungjin, Chen Zhengjia, Nannapaneni Sreenivas, Chen Amy Y, Moore Charles E, Sica Gabriel, Mosunjac Marina, Nguyen Minh Ly T, D'Souza Gypsyamber, Carey Thomas E, Peterson Lisa A, McHugh Jonathan B, Graham Martin, Komarck Christine M, Wolf Gregory T, Walline Heather M, Bellile Emily, Riddell James, Pai Sara I, Sidransky David, Westra William H, William William N, Lee J Jack, El-Naggar Adel K, Ferris Robert L, Seethala Raja, Grandis Jennifer R, Chen Zhuo Georgia, Saba Nabil F, Shin Dong M
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California.
Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.
We examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer).
Tissue microarrays (TMAs) were constructed using tumors from 41 disease site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-negative head and neck cancer controls. Expression of tumor biomarkers was assessed by immunohistochemistry (IHC) and correlations examined with clinical variables.
Expression levels of the studied oncogenic and inflammatory tumor biomarkers were not differentially regulated by HIV status. Among patients with HIV-positive head and neck cancer, laryngeal disease site (P = .003) and Clavien-Dindo classification IV (CD4) counts <200 cells/μL (P = .01) were associated with poor prognosis. Multivariate analysis showed that p16 positivity was associated with improved overall survival (OS; P < .001) whereas increased expression of transforming growth factor-beta (TGF-β) was associated with poor clinical outcome (P = .001).
Disease site has significant effect on the expression of biomarkers. Expression of tumor TGF-β could be a valuable addition to the conventional risk stratification equation for improving head and neck cancer disease management strategies.
我们研究了一组生物标志物对头颈部鳞状细胞癌（SCCHN）患者的预后价值，这些患者分为人类免疫缺陷病毒（HIV）阳性（HIV 阳性头颈部癌）和 HIV 阴性（HIV 阴性头颈部癌）。
使用来自 41 例疾病部位匹配且年龄匹配的 HIV 阳性头颈部癌病例和 44 例 HIV 阴性头颈部癌对照的肿瘤构建组织微阵列（TMA）。通过免疫组织化学（IHC）评估肿瘤生物标志物的表达，并检查其与临床变量的相关性。
所研究的致癌和炎性肿瘤生物标志物的表达水平不受 HIV 状态的差异调节。在 HIV 阳性头颈部癌患者中，喉部疾病部位（P = .003）和 Clavien-Dindo 分类 IV（CD4）计数<200 个细胞/μL（P = .01）与预后不良相关。多变量分析表明，p16 阳性与总体生存期（OS）改善相关（P < .001），而转化生长因子-β（TGF-β）表达增加与不良临床结局相关（P = .001）。
疾病部位对生物标志物的表达有显著影响。肿瘤 TGF-β 的表达可能是对传统风险分层方程的有价值补充，以改善头颈部癌疾病管理策略。
